FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2008
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Sanderling Venture Partners IV, L.P. 		2. Issuer Name and Ticker or Trading Symbol

CARDIONET INC [ BEAT ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

400 SOUTH EL CAMINO REAL, SUITE 1200 		3. Date of Earliest Transaction (MM/DD/YYYY)

3/25/2008
(Street)

SAN MATEO, CA 94402
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   3/25/2008     C    48909   A   (1) 53604   I   See footnote   (2)
Common Stock   3/25/2008     C    4685   A   (3) 58289   I   See footnote   (2)
Common Stock   3/25/2008     C    327630   A   (3) 327630   I   See footnote   (4)
Common Stock   3/25/2008     C    171611   A   (1) 188086   I   See footnote   (5)
Common Stock   3/25/2008     C    16438   A   (3) 204524   I   See footnote   (5)
Common Stock   3/25/2008     C    171978   A   (1) 188488   I   See footnote   (6)
Common Stock   3/25/2008     C    16474   A   (3) 204962   I   See footnote   (6)
Common Stock   3/25/2008     C    163798   A   (3) 163798   I   See footnote   (7)
Common Stock   3/25/2008     C    440827   A   (1) 483146   I   See footnote   (8)
Common Stock   3/25/2008     C    42227   A   (3) 525373   I   See footnote   (8)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock     (1) 3/25/2008     C        97819      (1)   (1) Common Stock   48909   $0   0   I   See footnote   (2)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        9370      (3)   (3) Common Stock   4685   $0   0   I   See footnote   (2)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        655261      (3)   (3) Common Stock   327630   $0   0   I   See footnote   (4)
Series B Convertible Preferred Stock     (1) 3/25/2008     C        343223      (1)   (1) Common Stock   171611   $0   0   I   See footnote   (5)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        32877      (3)   (3) Common Stock   16438   $0   0   I   See footnote   (5)
Series B Convertible Preferred Stock     (1) 3/25/2008     C        343957      (1)   (1) Common Stock   171978   $0   0   I   See footnote   (6)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        32948      (3)   (3) Common Stock   16474   $0   0   I   See footnote   (6)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        327596      (3)   (3) Common Stock   163798   $0   0   I   See footnote   (7)
Series B Convertible Preferred Stock     (1) 3/25/2008     C        881655      (1)   (1) Common Stock   440827   $0   0   I   See footnote   (8)
Series C Convertible Preferred Stock     (3) 3/25/2008     C        84454      (3)   (3) Common Stock   42227   $0   0   I   See footnote   (8)

Explanation of Responses:
( 1)  Each 2 shares of Series B Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 2)  By Sanderling [Feri Trust] Venture Partners IV, L.P. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil Investment Partners IV, L.P. the sole general partner of Sanderling [Feri Trust] Venture Partners IV, L.P. and has voting and investment power over the shares held by Sanderling [Feri Trust] Venture Partners IV, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 3)  Each 2 shares of Series C Convertible Preferred Stock converted into 1 share of the Issuer's common stock upon the closing of the initial public offering for no additional consideration and had no expiration date.
( 4)  By Sanderling IV Biomedical Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling IV Biomedical Co-Investment Fund, L.P. and has voting and investment power over the shares held by Sanderling IV Biomedical Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 5)  By Sanderling IV Biomedical, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling IV Biomedical, L.P. and has voting and investment power over the shares held by Sanderling IV Biomedical, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 6)  By Sanderling IV Limited Partnership. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil IV, L.P. the sole general partner of Sanderling IV Limited Partnership and has voting and investment power over the shares held by Sanderling IV Limited Partnership. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 7)  By Sanderling Venture Partners IV Co-Investment Fund, L.P. Fred Middleton, a member of the Issuer's board of directors is a managing director of Middleton, McNeil & Mills Associates IV, LLC the sole general partner of Sanderling Venture Partners IV Co-Investment Fund, L.P and has voting and investment power over the shares held by Sanderling Venture Partners IV Co-Investment Fund, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.
( 8)  By Sanderling Venture Partners IV, L.P. Fred Middleton, a member of the Issuer's board of directors is a general partner of Middleton-McNeil Associates IV, L.P. the sole general partner of Sanderling Venture Partners IV, L.P. and has voting and investment power over the shares held by Sanderling Venture Partners IV, L.P. Mr. Middleton disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein.

Remarks:
Exhibit 24.1 Power of Attorney

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Sanderling Venture Partners IV, L.P.
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X

Sanderling IV Limited Partnership
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X

Sanderling (Feri Trust) Venture Partners IV, L.P.
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X

SANDERLING IV BIOMEDICAL CO INVESTMENT FUND L P
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X

SANDERLING IV BIOMEDICAL L P
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X

SANDERLING VENTURE PARTNERS IV CO INVESTMENT FUND LP
400 SOUTH EL CAMINO REAL
SUITE 1200
SAN MATEO, CA 94402
X


Signatures
See Ex. 99.1 3/26/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more HeartBeam Charts.
HeartBeam (NASDAQ:BEAT)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more HeartBeam Charts.